Format

Send to

Choose Destination
Eur Urol. 2018 Apr;73(4):524-532. doi: 10.1016/j.eururo.2017.02.038. Epub 2017 Mar 19.

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Author information

1
Vancouver Prostate Centre & Laboratory for Advanced Genome Analysis, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
2
Vancouver Prostate Centre & Laboratory for Advanced Genome Analysis, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada.
3
Research and Development, GenomeDx Biosciences, Vancouver, BC, Canada.
4
Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada.
5
Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada.
6
Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, USA.
7
Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
8
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
9
Department of Urology, James Buchanan Brady Urological Institute, Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA; Department of Urology, Northwestern University School of Medicine, Chicago, IL, USA.
10
Department of Urology, James Buchanan Brady Urological Institute, Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
11
Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
12
School of Computing Sciences, Simon Fraser University, Burnaby, BC, Canada; School of Informatics and Computing, Indiana University, Bloomington, IN, USA.
13
BGI-Shenzhen, Shenzhen, China.
14
Vancouver Prostate Centre & Laboratory for Advanced Genome Analysis, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada. Electronic address: ywang@bccrc.ca.
15
Vancouver Prostate Centre & Laboratory for Advanced Genome Analysis, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; School of Computing Sciences, Simon Fraser University, Burnaby, BC, Canada. Electronic address: ccollins@prostatecentre.com.

Abstract

BACKGROUND:

Clinical grading systems using clinical features alongside nomograms lack precision in guiding treatment decisions in prostate cancer (PCa). There is a critical need for identification of biomarkers that can more accurately stratify patients with primary PCa.

OBJECTIVE:

To identify a robust prognostic signature to better distinguish indolent from aggressive prostate cancer (PCa).

DESIGN, SETTING, AND PARTICIPANTS:

To develop the signature, whole-genome and whole-transcriptome sequencing was conducted on five PCa patient-derived xenograft (PDX) models collected from independent foci of a single primary tumor and exhibiting variable metastatic phenotypes. Multiple independent clinical cohorts including an intermediate-risk cohort were used to validate the biomarkers.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

The outcome measurement defining aggressive PCa was metastasis following radical prostatectomy. A generalized linear model with lasso regularization was used to build a 93-gene stroma-derived metastasis signature (SDMS). The SDMS association with metastasis was assessed using a Wilcoxon rank-sum test. Performance was evaluated using the area under the curve (AUC) for the receiver operating characteristic, and Kaplan-Meier curves. Univariable and multivariable regression models were used to compare the SDMS alongside clinicopathological variables and reported signatures. AUC was assessed to determine if SDMS is additive or synergistic to previously reported signatures.

RESULTS AND LIMITATIONS:

A close association between stromal gene expression and metastatic phenotype was observed. Accordingly, the SDMS was modeled and validated in multiple independent clinical cohorts. Patients with higher SDMS scores were found to have worse prognosis. Furthermore, SDMS was an independent prognostic factor, can stratify risk in intermediate-risk PCa, and can improve the performance of other previously reported signatures.

CONCLUSIONS:

Profiling of stromal gene expression led to development of an SDMS that was validated as independently prognostic for the metastatic potential of prostate tumors.

PATIENT SUMMARY:

Our stroma-derived metastasis signature can predict the metastatic potential of early stage disease and will strengthen decisions regarding selection of active surveillance versus surgery and/or radiation therapy for prostate cancer patients. Furthermore, profiling of stroma cells should be more consistent than profiling of diverse cellular populations of heterogeneous tumors.

KEYWORDS:

Genomic profiling; Prognostic biomarkers; Prostate cancer metastasis; RNA sequencing; Stromal gene

PMID:
28330676
DOI:
10.1016/j.eururo.2017.02.038
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center